4760 Results

People

  1. Berger
    Berger
  2. Motzer
    Motzer
  3. Giralt
    Giralt
  4. Perales
    Perales
  5. Lee
    Lee
  6. Hudis
    Hudis
  7. Morrow
    Morrow
  8. Levine
    Levine
  9. Reis-Filho
    Reis-Filho
  10. Solit
    Solit

Groups

  1. Department of Medicine (1963)
  2. GSK Faculty (1162)
  3. Solid Tumor Oncology Division (1064)
  4. Surgery (904)
  5. Survivorship Research (795)
  6. Center for Hematologic Malignancies (777)
  7. Sloan Kettering Institute Postdocs (739)
  8. Hematologic Malignancies, Division of (725)
  9. Department of Pathology and Laboratory Medicine (655)
  10. Population Sciences Research Program (574)
  1. "2016"
Formats
  1. Journal Article (2949)
  2. Meeting Abstract (1606)
  3. Book Section (155)
  4. Conference Paper (36)
  5. Book Whole (14)
Groups
  1. Department of Medicine (1963)
  2. GSK Faculty (1162)
  3. Solid Tumor Oncology Division (1064)
  4. Surgery (904)
  5. Survivorship Research (795)
  6. Center for Hematologic Malignancies (777)

More Groups

People
  1. Michael Berger (93)
  2. Jedd Wolchok (84)
  3. Robert Motzer (74)
  4. Sergio Giralt (73)
  5. Miguel-Angel Perales (69)
  6. Jose Baselga (67)

More People

Years
  1. 2016 (4760)
Publications
  1. Journal of Clinical Oncology (469)
  2. Blood (210)
  3. Modern Pathology (124)
  4. Laboratory Investigation (108)
  5. International Journal of Radiation Oncology, Biology, Physics (104)
  6. Annals of Oncology (94)

More Publications

Publishers
  1. Elsevier Inc. (519)
  2. American Society of Clinical Oncology (497)
  3. Springer (349)
  4. Nature Publishing Group (322)
  5. Oxford University Press (248)
  6. American Society of Hematology (213)

More Publishers

Results (4760)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated results of a phase 1 study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M
    Meeting Abstract

    Tan, D. S. W.; Yang, J. C. H.; Leighl, N. B.; Riely, G. J.; Sequist, L. V.; Felip, E.; Seto, T.; Wolf, J.; Moody, S. E.; Adams, K.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates
    Meeting Abstract

    Tang, C.; Welsh, J. W.; de Groot, P.; Massarelli, E.; Chang, J. Y.; Hess, K. R.; Curran, M. A.; Cabanillas, M. E.; Subbiah, V.; Fu, S.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase I/randomized phase II study of MLN0128 v.s pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304
    Meeting Abstract

    Tap, W. D.; Mahoney, M. R.; Jaslowski, A. J.; Horvath, L. E.; Schwartz, G.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Genomic landscape of defective DNA damage response and repair mechanisms (DDR) across cancer types
    Meeting Abstract

    Teo, M.; Zabor, E. C.; Iyer, G.; Bambury, R.; Boyd, M. E.; Rosenberg, J. E.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARCO28 - A multicenter phase II study
    Meeting Abstract

    Tawbi, H. A. H.; Burgess, M. A.; Crowley, J.; Van Tine, B. A.; Hu, J.; Schuetze, S.; D'Angelo, S. P.; Attia, S.; Priebat, D. A.; Okuno, S. H.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Romiplostim management of chemotherapy-induced thrombocytopenia
    Meeting Abstract

    Soff, G. A.; Parameswaran, R.; Mantha, S.; Miao, Y.; Mones, J. V.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • An evaluation of the chronic lymphocytic leukemia (CLL) international prognostic index as a prognostic tool in patients with relapsed/refractory CLL in idelalisib phase 3 randomized studies
    Meeting Abstract

    Soumerai, J. D.; Barrientos, J. C.; Hallek, M.; Kipps, T. J.; Jones, J. A.; Stilgenbauer, S.; Xing, G.; Yao, N. S.; Ysebaert, L.; Zelenetz, A. D.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)
    Meeting Abstract

    Sweeney, C.; Xie, W.; Regan, M. M.; Nakabayashi, M.; Buyse, M. E.; Clarke, N. W.; Collette, L.; Dignam, J. J.; Fizazi, K.; Habibian, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia
    Meeting Abstract

    Tallman, M. S.; Feingold, J. M.; Spira, A. I.; Rizzieri, D.; Atallah, E. L.; Stock, W.; Jain, N.; Walter, R. B.; Chung, K. Y.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma
    Meeting Abstract

    Suzuki, M.; Cheung, I. Y.; Cheung, N. K. V.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save